Jardim DL - Search Results

1

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. Jardim DL, et al. Cancer Cell. 2021 Feb 8;39(2):154-173. doi: 10.1016/j.ccell.2020.10.001. Epub 2020 Oct 29. Cancer Cell. 2021. PMID: 33125859 Free PMC article. Review.

2

Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs.

Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS. Jardim DL, et al. Clin Cancer Res. 2014 Jan 15;20(2):281-8. doi: 10.1158/1078-0432.CCR-13-2103. Epub 2013 Nov 4. Clin Cancer Res. 2014. PMID: 24190980

3

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Jardim DL, et al. J Natl Cancer Inst. 2015 Sep 15;107(11):djv253. doi: 10.1093/jnci/djv253. Print 2015 Nov. J Natl Cancer Inst. 2015. PMID: 26378224 Free PMC article.

4

Response.

Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R. Jardim DL, et al. J Natl Cancer Inst. 2016 Feb 24;108(3):djw001. doi: 10.1093/jnci/djw001. Print 2016 Mar. J Natl Cancer Inst. 2016. PMID: 26912651 No abstract available.

5

An appraisal of drug development timelines in the Era of precision oncology.

Jardim DL, Schwaederle M, Hong DS, Kurzrock R. Jardim DL, et al. Oncotarget. 2016 Aug 16;7(33):53037-53046. doi: 10.18632/oncotarget.10588. Oncotarget. 2016. PMID: 27419632 Free PMC article.

6

Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review.

Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. Jardim DL, et al. Cancer Treat Rev. 2017 Jan;52:12-21. doi: 10.1016/j.ctrv.2016.10.009. Epub 2016 Nov 4. Cancer Treat Rev. 2017. PMID: 27883925 Review.

7

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R. Jardim DL, et al. Clin Cancer Res. 2018 Apr 15;24(8):1785-1794. doi: 10.1158/1078-0432.CCR-17-1970. Epub 2017 Dec 6. Clin Cancer Res. 2018. PMID: 29212781 Free PMC article. Review.

8

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology.

Jardim DL, de Melo Gagliato D, Kurzrock R. Jardim DL, et al. Integr Cancer Ther. 2018 Dec;17(4):1012-1015. doi: 10.1177/1534735418801524. Epub 2018 Sep 19. Integr Cancer Ther. 2018. PMID: 30229677 Free PMC article. Review.

9

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.

Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R. Millis SZ, et al. Among authors: jardim dl. Cancer. 2019 Apr 1;125(7):1185-1199. doi: 10.1002/cncr.31921. Epub 2018 Dec 24. Cancer. 2019. PMID: 30582752 Free PMC article.

10

Recent results of immunotherapy and perspectives for advanced NSCLC.

Jardim DL, de Melo Gagliato D. Jardim DL, et al. Lung Cancer Manag. 2016 Jun;5(2):57-60. doi: 10.2217/lmt-2016-0007. Epub 2016 May 24. Lung Cancer Manag. 2016. PMID: 30643550 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters